FDA Reviewing Advisory Panel Recommendation To Rescind Approval Of Avastin For Breast
 

FDA officials are reviewing an agency advisory panel's recommendation to revoke approval of Roche's Avastin for treatment of advanced breast cancer, the Washington Post reports. Each year, about 17,500 women with breast cancer are prescribed Avastin, which costs about $8,000 monthly...

More...